As hopes rise for pandemicâs close, some are preparing for never-ending COVID
Scores of companies, many in Massachusetts, gear up to fight the virus âin perpetuityâ
By Robert Weisman and Jonathan Saltzman Globe Staff,Updated April 24, 2021, 1 hour ago
Email to a Friend
Vaccinations are continuing in Boston at the Harvard Street Neighborhood Health Center clinic at the Prince Hall Grand Lodge. People may need booster shots in the future.Craig F. Walker/Globe Staff
A pandemic-weary public is dreaming of Memorial Day barbecues, summer nights at Fenway Park, and putting the long-running curse of COVID-19 behind us.
But in the medical and biopharma worlds, many are eyeing a more daunting prospect: coronavirus as a never-ending threat.
Proposed lab conversion of Liberty Mutual offices in Weston underscores growth of life sciences in the suburbs
bostonglobe.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bostonglobe.com Daily Mail and Mail on Sunday newspapers.
Mass Fintech Hub will seek to boost state s fintech industry - Boston Business Journal
bizjournals.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizjournals.com Daily Mail and Mail on Sunday newspapers.
Published: Mar 04, 2021 By Alex Keown
The year 2020 will be remembered for many things as it relates to the COVID-19 pandemic. For Massachusetts-based biopharma companies, 2020 was a banner year for investments that supported ongoing research and development.
The
Massachusetts Biotechnology Council (MassBio) 2020 Biopharma Funding Report released this week shows that biopharma companies within the state’s ecosystem raised $5.8 billion in venture funding, almost twice the $3 billion raised in 2019. That amount of funding was also $1 billion more than the 2018 high of $4.8 billion. The report shows that 41% of all biopharma venture funding went to Massachusetts-based biopharma companies.
Atea Pharmaceuticals, which develops antiviral therapeutics, raised the most through venture investments. The company secured
The Massachusetts biopharmaceutical industry raised far more investment than ever before in 2020, coinciding with the coronavirus pandemic that shifted an emphasis to potential lifesaving drugs, according to a report released Thursday.
The state s biopharma industry raised $5.8 billion last year, having never raised more than $5 billion in any year, according to the Massachusetts Biotechnology Council, a Cambridge-based statewide industry group. The Massachusetts biopharma industry was so dominant nationally 41% of all biopharma venture funding went to industry firms based in the state.
Most companies raising the highest levels of money were based in Boston, Cambridge or Waltham. None of the top 15 were outside the Route 128 belt, according to MassBio, and Cambridge firms alone made up 40% of venture capital funding in the state s industry, demonstrating how the booming industry is so densely centered in areas like Kendall Square in Cambridge and the Seaport in Boston.